A 2:1 Randomised Phase II Study of NivolUmab and Temozolomide vs Temozolomide in Methylated newly diagnosed Elderly Glioblastoma (NUTMEG)

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/GNT1125204

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Radiotherapy and Temozolomide (TMZ) chemotherapy treatment for the brain tumour glioblastoma (GBM) is not as effective in elderly patients. If their tumour has a genetic marker called "methylated MGMT", TMZ does work relatively better and is often given alone. Elderly GBM patients with this marker will be randomly selected in this trial to have TMZ alone or TMZ + Nivolumab - a drug that assists the immune system to attack cancer.

Funded Activity Details

Start Date: 01-01-2017

End Date: 01-01-2021

Funding Scheme: Project Grants

Funding Amount: $1,608,845.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Cancer Therapy (excl. Chemotherapy and Radiation Therapy)

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

brain tumours | cancer immunotherapy | elderly | glioblastoma | immunotherapy

Related Links